Today, genomics is saving countless lives and even entire species, thanks in large part to a commitment to collaborative and ...

This innovative software, CRISPRware, optimizes guide RNA design for genome editing, supporting research on genetic disorders ...

A Ph.D. student in biomolecular engineering at the University of California, Santa Cruz, has built a software program ...

I was just a baby scientist when I discovered the hormone that made Ozempic possible. I had no idea how life-changing—and ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Glucagon-like peptide-1 receptor agonists (GLP1RAs) are used to treat diabetes, obesity, and polycystic ovarian syndrome (PCOS) Semaglutide, liraglutide, lixisenatide, dulaglutide, and tirzepatide are ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant ...

Patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) appear to have a very low incidence of nonarteritic anterior ischemic optic neuropathy (NAION) when appropriately ...

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616-619.

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists ...

Other uses of glucagon-like peptide-1 drugs GLP-1 receptor signaling is crucial in neuroinflammation and neurodegeneration after brain injuries, stroke, or neurodegenerative diseases.